101. Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis.
- Author
-
Berge M, Chevalier P, Benammar M, Guillemain R, Amrein C, Lefeuvre S, Boussaud V, and Billaud EM
- Subjects
- Adult, Antifungal Agents adverse effects, Antifungal Agents therapeutic use, Aspergillosis prevention & control, Candidiasis prevention & control, Cystic Fibrosis drug therapy, Cytochrome P-450 CYP3A metabolism, Cytochrome P-450 CYP3A Inhibitors, Drug Interactions, Drug Monitoring, Drug-Related Side Effects and Adverse Reactions, Female, Graft Rejection prevention & control, Humans, Immunosuppressive Agents adverse effects, Itraconazole pharmacology, Male, Microbial Sensitivity Tests, Prescriptions, Pyrimidines pharmacology, Pyrimidines therapeutic use, Tacrolimus pharmacology, Tacrolimus therapeutic use, Triazoles adverse effects, Triazoles therapeutic use, Voriconazole, Antifungal Agents pharmacology, Cystic Fibrosis prevention & control, Enzyme Inhibitors pharmacology, Immunosuppressive Agents pharmacology, Lung Transplantation immunology, Mycoses prevention & control, Triazoles pharmacology
- Abstract
Oral posaconazole (PSZ), an azole antifungal drug, was recently introduced for the treatment of invasive fungal infections. The prescription of PSZ together with the immunosuppressant tacrolimus (TRL) was evaluated in 14 lung transplant patients with cystic fibrosis. PSZ inhibited CYP3A4 TRL metabolism, resulting in a decrease of TRL dose by a factor of 3, with tapering to a mean of 2 mg/d. Previous studies with itraconazole and voriconazole showed that TRL dose could be decreased by factors of 5 and 4, respectively. Joint therapeutic drug monitoring of TRL and PSZ was carried out to investigate the high risk of interindividual variability associated with this coprescription in such patients.
- Published
- 2009
- Full Text
- View/download PDF